Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of Cisplatin-loaded poly butyl cyanoacrylate nanoparticles on the ovarian cancer: an in vitro study

  • Research Article
  • Published:
Tumor Biology

Abstract

One of the main challenges of treatment of ovarian cancer is initial response to treatment and then acquisition of resistance to Cisplatin. Nanotechnology-based approaches are considered as one way to overcome drug resistance. In this study, the cytotoxicity effects of Cisplatin-loaded poly butyl cyanoacrylate (PBCA) nanoparticles (NPs) on the ovarian cancer cell line A2780cp resistant to Cisplatin were studied. NPs were synthesized by miniemulsion polymerization method. Size, size distribution and zeta potential of NPs were estimated as 489 nm, 0.429, and −20 mV, respectively. Drug loading and encapsulation efficiency were recognized as 5 % and 25 %, respectively. Drug release pattern (3.18 % release after 51 h) demonstrated high level of retention. Toxicological studies showed that cytotoxicity of the nanodrug Cisplatin was about three times as much as that of a free drug. Moreover, NPs presented acceptable stability after 2 months. The results of study suggest the use of this formulation for in vivo experiments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Kim JH, Chung HH, Jeong MS, Song MR, Kang KW, Kim JS. One step detection of circulating tumor cells in ovarian cancer using enhanced fluorescent silica nanoparticles. Int J Nanomed. 2013;8:2247–57.

    Google Scholar 

  2. Zhang J, Kan Y, Tian Y, Wang Z, Zhang J. Effects of poly (ADP ribosyl) polymerase (PARP) inhibitor on cisplatin resistance and proliferation of the ovariancancer C13* cells. Indian J Med Res. 2013;137:527–32.

    CAS  PubMed Central  PubMed  Google Scholar 

  3. Giaccone G. Clinical perspectives on platinum resistance. Drugs. 2000;59:9–17.

    Article  CAS  PubMed  Google Scholar 

  4. Saleh RM, Awadin WF, Elseady YY, Waheish FE. Renal and cardiovascular damage induced by cisplatin in rats. Life Sci J. 2014;11:191–203.

    Google Scholar 

  5. Cao Z, Tong R, Mishra A, Xu W, Wong GC, Cheng J, et al. Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angew Chem Int Ed Engl. 2009;48:6494–8.

    Article  CAS  PubMed  Google Scholar 

  6. Sutradhar KB, and Amin MDL. Nanotechnology in cancer drug delivery and selective targeting. ISRN Nanotechnol. 2014;2014: ID 939378.

  7. Zamboni WC, Torchilin V, Patri AK, Hrkach J, Stern S, Lee R, et al. Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance. Clin Cancer Res. 2012;18:3229–41.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Bandak S, Goren D, Horowitz A, Tzemach D, Gabizon A. Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anticancer Drugs. 1999;10:911–20.

    Article  CAS  PubMed  Google Scholar 

  9. Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol. 1999;43:1–7.

    Article  CAS  PubMed  Google Scholar 

  10. Vaage J, Donovan D, Wipff E, Abra R, Colbern G, Uster P, et al. Therapy of a xenografted human colonic carcinoma using cisplatin or doxorubicin encapsulated in long-circulating pegylated stealth liposomes. Int J Cancer. 1999;80:134–7.

    Article  CAS  PubMed  Google Scholar 

  11. Hirai M, Minematsu H, Hiramatsu Y, Kitagawa H, Otani T, Iwashita S, et al. Novel and simple loading procedure of cisplatin into liposomes and targeting tumor endothelial cells. Int J Pharm. 2010;391:274–83.

    Article  CAS  PubMed  Google Scholar 

  12. Huang CY, Chen CM, Lee YD. Synthesis of high loading and encapsulation efficient paclitaxel-loaded poly(n-butyl cyanoacrylate) nanoparticles via miniemulsion. Int J Pharm. 2007;338:267–75.

    Article  CAS  PubMed  Google Scholar 

  13. Andrieux K, Couvreur P. Polyalkylcyanoacrylate nanoparticles for delivery of drugs across the blood–brain barrier. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009;1:463–74.

    Article  CAS  PubMed  Google Scholar 

  14. Man W, Frochot C, Dellacherie E, Marie E. Well-defined poly(butyl cyanoacrylate) nanoparticles via miniemulsion polymerization. Macromol Symp. 2009;281:39–46.

    Article  Google Scholar 

  15. Wu M, Dellacherie E, Durand A, Marie E. Poly(n-butyl cyanoacrylate) nanoparticles via miniemulsion polymerization 2. PEG-based surfactants. Colloids Surf B: Biointerfaces. 2009;69:147–51.

    Article  CAS  PubMed  Google Scholar 

  16. Antonietti M, Landfester K. Polyreactions in miniemulsions. Prog Polym Sci. 2002;27:689–757.

    Article  CAS  Google Scholar 

  17. Savrikar SS, Lagad CE. Study of preparation and standardization of ‘Maadhutailika Basti’ with special reference to emulsion stability. Ayu. 2010;31:1–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Fontes G, Amaral P, Nele M, Coelho M. Factorial design to optimize biosurfactant production by Yarrowia lipolytica. J Biomed Biotechnol. 2010;2010:1–8.

    Google Scholar 

  19. Müller RH, Lherm C, Herbort J, Couvreur P. In vitro model for the degradation of alkylcyanoacrylate nanoparticles. Biomaterials. 1990;11:590–5.

    Article  PubMed  Google Scholar 

  20. Macka M, Borák J, Seménková L, Kiss F. Decomposition of cisplatin in aqueous solutions containing chlorides by ultrasonic energy and light. J Pharm Sci. 1994;83:815–8.

    Article  CAS  PubMed  Google Scholar 

  21. Wang X, Yang L, Chen ZG, Shin DM. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin. 2008;58:97–110.

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Biochemistry and Biophysics, Babol University of Medical Science, Babol, Iran

    Seyed Kazem Bagherpour Doun

  2. Department of Pilot Nanobiotechnology, Pasteur Institute of Iran, Tehran, Iran

    Seyed Kazem Bagherpour Doun, Seyed Ebrahim Alavi, Maedeh Koohi Moftakhari Esfahani, Hasan Ebrahimi Shahmabadi & Somaye Hamzei

  3. Department of Chemistry University of Tehran, Tehran, Iran

    Fatemeh Alavi

Authors
  1. Seyed Kazem Bagherpour Doun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seyed Ebrahim Alavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maedeh Koohi Moftakhari Esfahani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hasan Ebrahimi Shahmabadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fatemeh Alavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Somaye Hamzei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Seyed Ebrahim Alavi or Maedeh Koohi Moftakhari Esfahani.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bagherpour Doun, S.K., Alavi, S.E., Koohi Moftakhari Esfahani, M. et al. Efficacy of Cisplatin-loaded poly butyl cyanoacrylate nanoparticles on the ovarian cancer: an in vitro study. Tumor Biol. 35, 7491–7497 (2014). https://doi.org/10.1007/s13277-014-1996-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-1996-8

Keywords

Search

Navigation